Common Stock
- Symbol
- PHIO
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Phio Pharmaceuticals Corp.
PHIONASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On October 13, 2026, the Company issued a press release announcing the successful completion of its first commercial-scale cGMP Batch of PH-762 drug substance, a key operational milestone that supports the planned initiation of the Company's Phase 2b clinical trial in the first quarter of 2027.…
Company context
Phio (“Phio”, “we”, “our”, or the “Company”) is a clinical stage biotechnology company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future.
Current securities
Registered securities in this filing
PHIO PHARMACEUTICALS CORP. · 8-K · Filed 2026-10-13
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On October 13, 2026, the Company issued a press release announcing the successful completion of its first commercial-scale cGMP Batch of PH-762 drug substance, a key operational milestone that supports the planned initiation of the Company's Phase 2b clinical trial in the first quarter of 2027.
The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.